You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. STTR Phase I: Development and Validation of Low-Cost Natural Gas Leak Detection Sensors and Analytics for Drone-Based and Handheld Deployments

    SBC: Nikira Labs Inc.            Topic: CT

    The broader impact/commercial potential of this project is the rapid, cost-effective detection of natural gas leakage to improve public safety, mitigate global climate change, and decrease product loss. Natural gas is the largest provider of power in the United States. However, more than 80 Tg of leakage occurs at well pads and pipelines during production alone. Such leakage poses a public health ...

    STTR Phase I 2018 National Science Foundation
  2. STTR Phase II: Autonomous Landing of Small Unmanned Aircraft Systems onto Moving Platforms

    SBC: PLANCK AEROSYSTEMS INC.            Topic: EW

    The broader impact/commercial potential of this project will enable Unmanned Aerial Systems (UAS or drones) to safely and reliably operate from moving vehicles and moving vessels at sea. There is an immediate need for this capability in many industries. In commercial fishing, drones will replace manned aircraft for fish-finding operations, radically reducing cost and risk. In maritime security, dr ...

    STTR Phase II 2018 National Science Foundation
  3. STTR Phase II: Nanostraw-mediated Immune Cell Reprogramming

    SBC: Navan Technologies, Inc.            Topic: BT

    The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase II project will be to develop a new tool to safely and nondestructively deliver genes and other materials into large numbers cells at the same time. New forms of therapies for cancer and other intractable diseases take advantage of a patient's own cells, re-engineered in the laboratory to target a tumor ...

    STTR Phase II 2018 National Science Foundation
  4. STTR Phase II: Occupancy Estimation and Energy Savings with True Presence Sensors

    SBC: ADNOVIV, INC.            Topic: EW

    The broader impact/commercial potential of this project will extend to a number of applications, including smart buildings, home automation, and security. The development of this new technology for efficient indoor sensing, and development of new algorithms for occupancy sensing and counting techniques, will have immediate implications in the building automation and home construction industries, w ...

    STTR Phase II 2018 National Science Foundation
  5. STTR Phase I: A Mobile Triage Application for Reducing the Risk of COPD Exacerbations

    SBC: REVON SYSTEMS, INC            Topic: SH

    The broader impact/commercial potential of this Small Business Technology Transfer (STTR) project is the reduction of significant disease flare-ups in patients with Chronic Obstructive Pulmonary Disease (COPD), increase in patient quality-of-life, and a reduction of expensive and unnecessary healthcare utilization. Current at-home care support for COPD patients is often completely missing or consi ...

    STTR Phase I 2018 National Science Foundation
  6. STTR Phase I: Advanced Thermophotovoltaic Generators for High-Value Remote Power

    SBC: Marigold Power, Inc.            Topic: PH

    The broader impact / commercial potential of this Small Business Technology Transfer (STTR) Phase I project is to enable electrification of remote oil & gas processes to reduce methane emissions, improve on-site safety, and provide leak-detection and monitoring capabilities. This will be achieved by developing a robust, efficient, small-scale power generator capable of converting on-site fuel to e ...

    STTR Phase I 2018 National Science Foundation
  7. Novel Circulating RNA-based Markers as Diagnostic Biomarkers of Infectious Diseases

    SBC: CFD Research Corporation            Topic: CBD18A001

    In resource limited settings, rapid and accurate diagnosis of infections is critical for managing potential exposures to highly virulent pathogens,whether occurring from an act of bioterrorism or a natural event. This is especially important for hard to detect intracellular bacterial andalphavirus infections, that overlap symptomatically and often treated empirically due to a lack of reliable and ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  8. Marburg Virus Prophylactic Medical Countermeasure

    SBC: MAPP BIOPHARMACEUTICAL, INC.            Topic: CBD18A002

    There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terriblemorbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditionalvaccines have proven to be a huge contribution to public health, they do have some limitations especially in the cont ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  9. Marburg Virus Prophylactic Medical Countermeasure

    SBC: Flow Pharma, Inc.            Topic: CBD18A002

    Flow Pharma, Inc. is a biotechnology company in the San Francisco Bay Area developing fully synthetic cytotoxic T lymphocyte (CTL)stimulating peptide vaccines for Marburg virus. The FlowVax vaccine platform allows us to create dry powder formulations of biodegradablemicrospheres and TLR adjuvants incorporating class I and class II T cell epitopes. FlowVax vaccines can be designed for delivery by i ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  10. Infectious Disease Diagnostics and Differentiation of Viral vs. Bacterial Infections for Point ofCare Applications

    SBC: GENECAPTURE            Topic: CBD15C001

    GeneCapture, Inc. is proposing to develop a rapid in vitro diagnostic prototype using our patented molecular-based CAPTURE (ConfirmActive Pathogens Through Unamplified RNA Expression) assay. Based on the results and experience gained in our Phase I STTR contractHDTRA1-16C-0061: Infectious Disease Diagnostics and Differentiation of Viral vs. Bacterial Infections for Point of Care Applications, we p ...

    STTR Phase II 2018 Department of DefenseOffice for Chemical and Biological Defense
US Flag An Official Website of the United States Government